Advertisement

Hodgkin Lymphoma

  • Bradford S. Hoppe
  • Richard T. Hoppe
Chapter
Part of the Medical Radiology book series (MEDRAD)

Introduction

Table 1

ILROG planning definitions for ISRT in lymphoma (Specht et al. 2013; Illidge 2014)

Volume

Description

Gross tumor volume (GTV)

Pre-chemotherapy/surgery GTV (GTVp)

Contains gross tumor volume as identified on diagnostic imaging prior to chemotherapy and/or surgery

Post-chemotherapy/surgery GTV (GTVr)

Contains gross tumor volume as identified on diagnostic and/or planning imaging after management with chemotherapy and/or surgery

No prior treatment GTV (GTV)

Contains gross tumor volume identified on diagnostic and/or planning imaging in the absence of prior chemotherapy or surgery (e.g., in the case of primary or salvage RT)

Clinical target volume (CTV)

Contains entire post-chemotherapy/surgery or “no prior treatment” GTV

Generally contains pre-chemotherapy/surgery GTV (unless volume is unable to be safely treating in its entirety)

Excludes extent of pre-chemotherapy/surgery GTV that displaced normal, uninvolved tissue (bone, organs, muscles, etc.) prior to...

Keywords

Planning Target Volume Hodgkin Lymphoma Clinical Target Volume Target Volume Delineation Deep Inspiration Breath Hold 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Engert A, Plutschow A, Eich HT et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):640–652CrossRefPubMedGoogle Scholar
  2. Girinsky T, van der Maazen R, Specht L et al (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79(3):270–277CrossRefPubMedPubMedCentralGoogle Scholar
  3. Hoppe RT, Advani RH, Ai WZ et al (2012a) Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10(5):589–597CrossRefPubMedGoogle Scholar
  4. Hoppe BS, Flampouri S, Su Z et al (2012b) Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study. Int J Radiat Oncol Biol Phys 83(1):260–267CrossRefPubMedGoogle Scholar
  5. Illidge T, Specht L, Yahalom J (2014) Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. IJROBP 89 (1):49–58CrossRefGoogle Scholar
  6. Meyer RM, Gospodarowicz MK, Connors JM et al (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366(5):399–408CrossRefPubMedGoogle Scholar
  7. Specht L, Yahalom J, Illidge T et al (2013) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol PhysGoogle Scholar
  8. Travis LB, Gospodarowicz M et al (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94:182–92Google Scholar
  9. Travis LB, Hill DA et al (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465–75Google Scholar
  10. Tukenova M, Guibout C et al (2010) Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28:1308–15.CrossRefPubMedGoogle Scholar
  11. Yahalom J, Mauch P (2002) The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol 13(Suppl 1):79–83CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Department of Radiation OncologyUniversity of FloridaJacksonvilleUSA
  2. 2.Department of Radiation OncologyStanford UniversityPalo Alto, StanfordUSA

Personalised recommendations